Cargando…

Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis

Periostin is known to be a useful biomarker for various diseases. In this article, we focus on allergic diseases and pulmonary fibrosis, for which we and others are now developing detection systems for periostin as a biomarker. Biomarker-based precision medicine in the management of type 2 inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Junya, Takai, Masayuki, Kamei, Ayami, Azuma, Yoshinori, Izuhara, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391913/
https://www.ncbi.nlm.nih.gov/pubmed/34439751
http://dx.doi.org/10.3390/biom11081084
_version_ 1783743383793041408
author Ono, Junya
Takai, Masayuki
Kamei, Ayami
Azuma, Yoshinori
Izuhara, Kenji
author_facet Ono, Junya
Takai, Masayuki
Kamei, Ayami
Azuma, Yoshinori
Izuhara, Kenji
author_sort Ono, Junya
collection PubMed
description Periostin is known to be a useful biomarker for various diseases. In this article, we focus on allergic diseases and pulmonary fibrosis, for which we and others are now developing detection systems for periostin as a biomarker. Biomarker-based precision medicine in the management of type 2 inflammation and fibrotic diseases since heterogeneity is of utmost importance. Periostin expression is induced by type 2 cytokines (interleukin-4/-13) or transforming growth factor-β, and plays a vital role in the pathogenesis of allergic inflammation or interstitial lung disease, respectively, andits serum levels are correlated disease severity, prognosis and responsiveness to the treatment. We first summarise the importance of type 2 biomarker and then describe the pathological role of periostin in the development and progression of type 2 allergic inflammation and pulmonary fibrosis. In addition, then, we summarise the recent development of assay methods for periostin detection, and analyse the diseases in which periostin concentration is elevated in serum and local biological fluids and its usefulness as a biomarker. Furthermore, we describe recent findings of periostin as a biomarker in the use of biologics or anti-fibrotic therapy. Finally, we describe the factors that influence the change in periostin concentration under the healthy conditions.
format Online
Article
Text
id pubmed-8391913
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83919132021-08-28 Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis Ono, Junya Takai, Masayuki Kamei, Ayami Azuma, Yoshinori Izuhara, Kenji Biomolecules Review Periostin is known to be a useful biomarker for various diseases. In this article, we focus on allergic diseases and pulmonary fibrosis, for which we and others are now developing detection systems for periostin as a biomarker. Biomarker-based precision medicine in the management of type 2 inflammation and fibrotic diseases since heterogeneity is of utmost importance. Periostin expression is induced by type 2 cytokines (interleukin-4/-13) or transforming growth factor-β, and plays a vital role in the pathogenesis of allergic inflammation or interstitial lung disease, respectively, andits serum levels are correlated disease severity, prognosis and responsiveness to the treatment. We first summarise the importance of type 2 biomarker and then describe the pathological role of periostin in the development and progression of type 2 allergic inflammation and pulmonary fibrosis. In addition, then, we summarise the recent development of assay methods for periostin detection, and analyse the diseases in which periostin concentration is elevated in serum and local biological fluids and its usefulness as a biomarker. Furthermore, we describe recent findings of periostin as a biomarker in the use of biologics or anti-fibrotic therapy. Finally, we describe the factors that influence the change in periostin concentration under the healthy conditions. MDPI 2021-07-22 /pmc/articles/PMC8391913/ /pubmed/34439751 http://dx.doi.org/10.3390/biom11081084 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ono, Junya
Takai, Masayuki
Kamei, Ayami
Azuma, Yoshinori
Izuhara, Kenji
Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title_full Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title_fullStr Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title_full_unstemmed Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title_short Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis
title_sort pathological roles and clinical usefulness of periostin in type 2 inflammation and pulmonary fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391913/
https://www.ncbi.nlm.nih.gov/pubmed/34439751
http://dx.doi.org/10.3390/biom11081084
work_keys_str_mv AT onojunya pathologicalrolesandclinicalusefulnessofperiostinintype2inflammationandpulmonaryfibrosis
AT takaimasayuki pathologicalrolesandclinicalusefulnessofperiostinintype2inflammationandpulmonaryfibrosis
AT kameiayami pathologicalrolesandclinicalusefulnessofperiostinintype2inflammationandpulmonaryfibrosis
AT azumayoshinori pathologicalrolesandclinicalusefulnessofperiostinintype2inflammationandpulmonaryfibrosis
AT izuharakenji pathologicalrolesandclinicalusefulnessofperiostinintype2inflammationandpulmonaryfibrosis